NCT03896269 2026-04-14
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
10 trialsNCT04049539 2026-04-08
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04990102 2026-03-23
Phase IB/II of CPX-351 for Relapse Prevention in AML
Georgetown University
Phase 1/2 Recruiting
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT05558124 2026-02-27
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT03629171 2026-02-20
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT04128748 2025-12-17
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04493164 2025-11-21
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07008638 2025-07-09
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 1/2 Recruiting